The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea (narsoplimab-wuug) for hematopoietic stem cell transplant- associated thrombotic ...
A study reveals the gut microbiome's role in predicting multiple myeloma outcomes, highlighting butyrate-producing bacteria ...
It is the first evidence that MCL patients in complete remission, with undetectable minimal residual disease (MRD), may be able to rely on highly effective standard treatments and avoid the rigors of ...
Transplanted autologous corneal stem cells successfully repaired corneal injuries in patients. Over 90% of patients achieved complete or partial success. The procedure proved safe with no serious ...
A diagnosis of acquired von Willebrand disease and stage 2 multiple myeloma followed unusual symptoms, leading to extensive testing. Treatment included a four-drug chemotherapy regimen and an ...
Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback